FDA concerns over sterility of products prompted a voluntary recall by Westborough, Mass.-based Ameridose of all its unexpired products in circulation, according to the American Society of Anesthesiology.
The FDA is currently conducting an inspection of the facility, and its preliminary findings have raised concerns about sterility assurance for all products produced and distributed by the facility.
The recall was not based on reports of patients with infections from Ameridose products, but rather a precaution since Ameridose shares common management with New England Compounding Center, the firm associated with the compounding drugs linked to the meningitis outbreak.
For a full list of Ameridose products, visit their site.
More Articles on Anesthesia:
Watching Videos Before Anesthesia Induction Reduces Stress in Children
Dicolfenac Provides Significant Pain Relief for Abdominal, Pelvic Surgeries
Can ASCs Still Profit From Anesthesia? A Review of OIG Guidance
The FDA is currently conducting an inspection of the facility, and its preliminary findings have raised concerns about sterility assurance for all products produced and distributed by the facility.
The recall was not based on reports of patients with infections from Ameridose products, but rather a precaution since Ameridose shares common management with New England Compounding Center, the firm associated with the compounding drugs linked to the meningitis outbreak.
For a full list of Ameridose products, visit their site.
More Articles on Anesthesia:
Watching Videos Before Anesthesia Induction Reduces Stress in Children
Dicolfenac Provides Significant Pain Relief for Abdominal, Pelvic Surgeries
Can ASCs Still Profit From Anesthesia? A Review of OIG Guidance